← Leaderboards
Michael Marcel Lederman
Case Western Reserve University
$51,371,852
Attributed
$60,457,879
Total exposure
29
Grants
19
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $9.5M · FY2005–20$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$97,577,957 · 34
By mechanism
U01$34,567,829 · 3
P01$22,826,186 · 5
UM1$15,624,765 · 1
P30$13,476,578 · 5
U19$7,080,877 · 3
R33$1,463,311 · 1
Top collaborators
- Benigno Rodriguez9 shared
- Mirko Paiardini6 shared
Most similar at Case Western Reserve University
Same institution · by research overlap
- Nicholas T. Funderburg$7,518,795
- Eric J Arts$12,120,161
- Derek W Abbott$15,447,395
Others in their field
Top investigators on “Hiv Infections”
- Wafaa M. El-Sadr · Columbia University Health Sciences$965,259,079
- Lawrence Corey · Fred Hutchinson Cancer Center$728,701,834
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$467,263,656
- Judith S. Currier · University Of California Los Angeles$466,447,923
- Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$398,445,678
Research focus
Hiv InfectionsClinical ResearchResearch PersonnelImmuneInfectionSiteHuman Therapy EvaluationAntiviral AgentsHuman SubjectMemberBaseAcquired Immunodeficiency SyndromeInflammationClinical TrialsExposure ToInflammatoryProgramsCellsLinkPathogenesisMicrobicideCytokineInstitutionDesign
Grant awards (118)
Mobilizing host defenses to lymphoid sites of HIV persistence to induce remission$897,741
R56 · FY2020 · AI
Clinical Services Core D$105,957
P30 · FY2020 · AI · contact PI
Clinical Services Core D$209,281
P30 · FY2019 · AI · contact PI
Regulatory T cell dysfunction in HIV-1/HCV drug users$199,650
R01 · FY2019 · DA · contact PI
Targeting Cytolytic Cells to Lymphoid Sites of HIV Persistence.$480,497
R33 · FY2018 · AI · contact PI
Regulatory T cell dysfunction in HIV-1/HCV drug users$199,650
R01 · FY2018 · DA · contact PI
Clinical Services Core D$187,147
P30 · FY2018 · AI · contact PI
Case Clinical Trials Unit$1,977,369
UM1 · FY2017 · AI · contact PI
Effects of IL-6 blockade in treated HIV infection$1,213,749
U01 · FY2017 · AI · contact PI
Targeting Cytolytic Cells to Lymphoid Sites of HIV Persistence.$490,442
R33 · FY2017 · AI · contact PI
Regulatory T cell dysfunction in HIV-1/HCV drug users$198,575
R01 · FY2017 · DA · contact PI
WG1: Immune Mechanisms and Pathogenesis$7,925
P30 · FY2017 · AI · contact PI
Case Clinical Trials Unit$2,553,716
UM1 · FY2016 · AI · contact PI
Effects of IL-6 blockade in treated HIV infection$1,603,285
U01 · FY2016 · AI · contact PI
Targeting Cytolytic Cells to Lymphoid Sites of HIV Persistence.$492,372
R33 · FY2016 · AI · contact PI
WG1: Immune Mechanisms and Pathogenesis$7,755
P30 · FY2016 · AI · contact PI
Case Clinical Trials Unit$1,908,328
UM1 · FY2015 · AI · contact PI
Effects of IL-6 blockade in treated HIV infection$1,062,447
U01 · FY2015 · AI · contact PI
Targeting Cytolytic Cells to Lymphoid Sites of HIV Persistence.$262,086
R21 · FY2015 · AI · contact PI
Case Clinical Trials Unit$3,065,181
UM1 · FY2014 · AI · contact PI
Effects of IL-6 blockade in treated HIV infection$1,190,652
U01 · FY2014 · AI · contact PI
Targeting Cytolytic Cells to Lymphoid Sites of HIV Persistence.$234,742
R21 · FY2014 · AI · contact PI
Case AIDS Clinical Trials Unit$2,944,131
UM1 · FY2013 · AI · contact PI
Effects of IL-6 blockade in treated HIV infection$739,447
U01 · FY2013 · AI · contact PI
Case AIDS Clinical Trials Unit$3,176,040
UM1 · FY2012 · AI · contact PI
Defining the Pathogenesis of Immune Deficiency in Chronic HIV Infection$1,912,693
P01 · FY2012 · AI · contact PI
Administrative Core$289,488
P01 · FY2012 · AI · contact PI
Bystander activation drives T cell losses in chronic HIV infection$276,511
P01 · FY2012 · AI · contact PI
Case AIDS Clinical Trials Unit$3,140,238
U01 · FY2011 · AI · contact PI
Defining the Pathogenesis of Immune Deficiency in Chronic HIV Infection$1,949,299
P01 · FY2011 · AI · contact PI
Bystander activation drives T cell losses in chronic HIV infection$288,701
P01 · FY2011 · AI · contact PI
Administrative Core$161,340
P01 · FY2011 · AI · contact PI
Case AIDS Clinical Trials Unit$3,573,700
U01 · FY2010 · AI · contact PI
Defining the Pathogenesis of Immune Deficiency in Chronic HIV Infection$2,399,969
P01 · FY2010 · AI · contact PI
Basic and Comparative Studies of CCR5 Inhibition to Prevent HIV Transmission$1,579,735
U19 · FY2010 · AI · contact PI
Basic and Comparative Studies of CCR5 Inhibition to Prevent HIV Transmission$963,378
U19 · FY2010 · AI · contact PI
Bystander activation drives T cell losses in chronic HIV infection$388,661
P01 · FY2010 · AI · contact PI
Developing RANTES analogues as topical strategies to prevent HIV transmission$297,296
U19 · FY2010 · AI · contact PI
Administrative Core$174,714
P01 · FY2010 · AI · contact PI
Administrative Core$166,468
U19 · FY2010 · AI · contact PI
Case AIDS Clinical Trials Unit$3,056,995
U01 · FY2009 · AI · contact PI
Defining the Pathogenesis of Immune Deficiency in Chronic HIV Infection$2,389,457
P01 · FY2009 · AI · contact PI
Basic and Comparative Studies of CCR5 Inhibition to Prevent HIV Transmission$1,552,707
U19 · FY2009 · AI · contact PI
Bystander activation drives T cell losses in chronic HIV infection$381,243
P01 · FY2009 · AI · contact PI
Developing RANTES analogues as topical strategies to prevent HIV transmission$291,708
U19 · FY2009 · AI · contact PI
Administrative Core$171,380
P01 · FY2009 · AI · contact PI
Administrative Core$163,999
U19 · FY2009 · AI · contact PI
Case AIDS Clinical Trials Unit$2,550,636
U01 · FY2008 · AI · contact PI
Defining the Pathogenesis of Immune Deficiency in Chronic HIV Infection$2,282,700
P01 · FY2008 · AI · contact PI
Basic and Comparative Studies of CCR5 Inhibition to Prevent HIV Transmission$1,585,769
U19 · FY2008 · AI · contact PI
Bystander activation drives T cell losses in chronic HIV infection$386,611
P01 · FY2008 · AI · contact PI
Developing RANTES analogues as topical strategies to prevent HIV transmission$301,793
U19 · FY2008 · AI · contact PI
CORE--Clinical Core$274,934
P30 · FY2008 · AI · contact PI
Administrative Core$184,251
P01 · FY2008 · AI · contact PI
Administrative Core$178,024
U19 · FY2008 · AI · contact PI
Case AIDS Clinical Trials Unit$2,405,283
U01 · FY2007 · AI · contact PI
CENTER FOR AIDS RESEARCH(CFAR)$1,598,632
P30 · FY2007 · AI · contact PI
CORE--Clinical Core$269,334
P30 · FY2007 · AI · contact PI
Topical Immune modulatory strategies to prevent HIV transmission$180,253
R21 · FY2007 · AI · contact PI
CENTER FOR AIDS RESEARCH(CFAR)$153,198
P30 · FY2007 · AI · contact PI
2007 Case CFAR Annual Spring Conference$23,160
R13 · FY2007 · AI · contact PI
CENTER FOR AIDS RESEARCH(CFAR)$1,990,746
P30 · FY2006 · AI · contact PI
ADULT AIDS CLINICAL TRIALS UNIT$1,753,886
U01 · FY2006 · AI · contact PI
Topical Agents to Prevent Mucosal HIV Transmission$1,731,034
P01 · FY2006 · AI · contact PI
ADULT AIDS CLINICAL TRIALS UNIT$258,138
U01 · FY2006 · AI · contact PI
Topical Immune modulatory strategies to prevent HIV transmission$225,399
R21 · FY2006 · AI · contact PI
CORE--Clinical Core$185,894
P30 · FY2006 · AI · contact PI
Case CFAR Meeting: HIV Pathogenesis$12,000
R13 · FY2006 · AI · contact PI
ACTG 5214 SINGLE DOSE IL-7 IN HIV-1 SUBJECTS RECEIVING ANTIRETROVIRAL TREATMENT$6,433
M01 · FY2006 · RR · contact PI
ADULT AIDS CLINICAL TRIALS UNIT$1,987,464
U01 · FY2005 · AI
CENTER FOR AIDS RESEARCH(CFAR)$1,561,245
P30 · FY2005 · AI
Topical Agents to Prevent Mucosal HIV Transmission$1,422,467
P01 · FY2005 · AI
Topical Agents to Prevent Mucosal HIV Transmission$401,497
P01 · FY2005 · AI
ADULT AIDS CLINICAL TRIALS UNIT$322,887
U01 · FY2005 · AI
Phase II Study of Glivic in African Kaposi's Sarcoma$207,824
P30 · FY2005 · AI
CORE--Clinical Core$181,201
P30 · FY2005 · AI
Antiretroviral Outcomes and Resistance in African Women$178,159
P30 · FY2005 · AI
Conference on HIV Pathogenesis$20,000
R13 · FY2005 · AI
ADULT AIDS CLINICAL TRIALS UNIT$1,978,951
U01 · FY2004 · AI
CENTER FOR AIDS RESEARCH(CFAR)$1,500,000
P30 · FY2004 · AI
Topical Agents to Prevent Mucosal HIV Transmission$1,384,105
P01 · FY2004 · AI
CORE--Clinical Core$173,499
P30 · FY2004 · AI
Immune Mechanisms and HIV Disease Pathogenesis$22,944
R13 · FY2004 · AI
ACTG A5147s Lopinavir/ritonavir vs GW433908 in HIV-1 pts with treatment failure$1,110
M01 · FY2004 · RR
ADULT AIDS CLINICAL TRIALS UNIT$2,047,755
U01 · FY2003 · AI
Topical Agents to Prevent Mucosal HIV Transmission$1,356,164
P01 · FY2003 · AI
CENTER FOR AIDS RESEARCH (CFAR)$750,000
P30 · FY2003 · AI
ADULT AIDS CLINICAL TRIALS UNIT$2,012,012
U01 · FY2002 · AI
CENTER FOR AIDS RESEARCH (CFAR)$1,292,713
P30 · FY2002 · AI
Topical Agents to Prevent Mucosal HIV Transmission$1,169,561
P01 · FY2002 · AI
CORE--CLINICAL RESEARCH$196,218
P30 · FY2002 · AI
ACTG 384--Protease inhibitor or reverse transcriptase inhibitor in HIV infection$0
M01 · FY2002 · RR
ACTG 928--TNF receptor on IL6, TNF alpha, &immune markers in HIV$0
M01 · FY2002 · RR
ACTG 301: MEMANTINE FOR AIDS DEMENTIA COMPLEX$0
M01 · FY2002 · RR
ACTG 328--INTERMITTENT RECOMBINANT HUMAN INTERLEUKIN-2$0
M01 · FY2002 · RR
Safety &antiviral activity of AMD3100 in HIV-1 infection$0
M01 · FY2002 · RR
ACTG 398--Amprenavir/abacavir/efavirenz/adeforvir dipivoxil in HIV infection$0
M01 · FY2002 · RR
ADULT AIDS CLINICAL TRIALS UNIT$1,917,734
U01 · FY2001 · AI
CENTER FOR AIDS RESEARCH (CFAR)$1,056,731
P30 · FY2001 · AI
DEVELOPMENT OF HIV CORECEPTOR INHIBITORS$874,524
P01 · FY2001 · AI
CORE--CLINICAL RESEARCH$196,218
P30 · FY2001 · AI
ACTG 328--INTERMITTENT RECOMBINANT HUMAN INTERLEUKIN-2$0
M01 · FY2001 · RR
Safety &antiviral activity of AMD3100 in HIV-1 infection$0
M01 · FY2001 · RR
ACTG 398--Amprenavir/abacavir/efavirenz/adeforvir dipivoxil in HIV infection$0
M01 · FY2001 · RR
ACTG 384--Protease inhibitor or reverse transcriptase inhibitor in HIV infection$0
M01 · FY2001 · RR
ACTG 928--TNF receptor on IL6, TNF alpha, &immune markers in HIV$0
M01 · FY2001 · RR
ACTG 301: MEMANTINE FOR AIDS DEMENTIA COMPLEX$0
M01 · FY2001 · RR
ADULT AIDS CLINICAL TRIALS UNIT$1,752,570
U01 · FY2000 · AI
CENTER FOR AIDS RESEARCH (CFAR)$1,025,955
P30 · FY2000 · AI
DEVELOPMENT OF HIV CORECEPTOR INHIBITORS$849,816
P01 · FY2000 · AI
CORE--CLINICAL RESEARCH$166,012
P30 · FY2000 · AI
ACTG 301: MEMANTINE FOR AIDS DEMENTIA COMPLEX$19,199
M01 · FY2000 · RR
ACTG 328--INTERMITTENT RECOMBINANT HUMAN INTERLEUKIN-2$19,199
M01 · FY2000 · RR
VIRAL ACTIVATION TRANSFUSION STUDY$16,270
N01 · FY2000 · HB
Safety &antiviral activity of AMD3100 in HIV-1 infection$0
M01 · FY2000 · RR
ACTG 398--Amprenavir/abacavir/efavirenz/adeforvir dipivoxil in HIV infection$0
M01 · FY2000 · RR
ACTG 384--Protease inhibitor or reverse transcriptase inhibitor in HIV infection$0
M01 · FY2000 · RR
ACTG 928--TNF receptor on IL6, TNF alpha, &immune markers in HIV$0
M01 · FY2000 · RR